In vivo

Treatment: IP, SC, IM, IV (bolus and infusion), intracerebral, intranasal and intratumoral injections, skin applications, oral and intrarectal administrations
Injection of radiolabelled compounds for PK and PD (¹⁴C, ³H, ¹²⁵I)
Administration of compounds, hormone supplements (estradiol…) in water or food
Tumor graft: SC, orthotopic (intrapleural, intrapancreatic…)
Tumor cell injection: SC, IV, IP, orthotopic (intracerebral, intraprostatic…)
Chemo-induction with carcinogens (DMBA, DMH…) by oral administration, skin application…
Surgery: castration, spaying, spleen and liver ablation, microsurgery, cardiac ischemia
Blood collection (cardiac punction, vein or artery of the tail, abdominal aorta, jugular vein…), organ and tissue collection, cardiac perfusion
Infusion: catheter implantation in the tail vein or femoral vein (long-term infusion)
Monitoring of tumor growth, animal body weight, survival, health status, randomization according to body weight or tumor volume
Monitoring of food consumption, support/monitoring of animals in metabolic cages
Removal of tissues or immunological cells for “ex-vivo” tests: preparation of cytochromes for enzymatic activity analysis, leukocyte quantification…
Production of tumor tissues for histology, tissue arrays, RNA extraction…

Evaluation of the antitumor activity of compounds using different animal models of cancer
Evaluation of immunotherapy using humanized mouse models
Chemoprevention study
Syngenic, xenograft models (human tumors), orthotopic, transgenic models
In vivo, antitumorigenicity studies
Evaluation of compound toxicity (hematotoxicity…)
Determination of therapeutic index
Study of therapeutic associations
Pharmocokinetic and pharmacodynamic studies
Development and characterization of custom-made experimental models
Metabolism studies
Histological and immunohistochemistry studies
Localized or whole-body radiotherapy (CGFL- Centre Leclerc)

All studies performed at Oncodesign are first submitted to an ethical committee.